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Summarn Clinical decision making is based on results from qualitative and quantitative information. To
provide quantitative data, various laboratory variables are widely used in the clinical evaluation of patients
with small-cell lung cancer (SCLC). The tumour marker serum neuron-specific enolase (S-NSE) and the
routine laboratory parameter serum lactate dehydrogenase (S-LDH) have been investigated, mostly separately.
Few studies have compared their importance in SCLC, especially in progressive disease (PD). The present
investigation was undertaken to evaluate S-NSE for diagnostic efficacy in PD and compare it with S-LDH. In
27 patients in a treatment trial of SCLC, regular follow-up laboratory values were prospectively obtained.
Chemotherapy was given according to trial protocols, and all clinical evaluation followed the WHO recom-
mendations. At re-evaluation all but three values had normalised (two S-NSE. one S-LDH). S-NSE at
progression was increased in 93% of the patients and S-LDH in 590*. The efficacy of S-NSE to discriminate
between response and PD was superior to S-LDH (0.92 vs 0.70). There was no additive effect of the two
parameters in prediction of PD. and the discriminating power was higher for S-NSE than for S-LDH
(P<0.0008). The disease status-related marker increments in relation to upper reference limits. i.e. the signal-
noise relation, were higher for S-NSE than for S-LD. Both of the markers carry information on PD. S-NSE is.
however, clearly superior to S-LDH in reflecting disease status during therapy. This prompts us to conclude
that S-NSE should replace S-LDH as prognostic factor and disease activity monitor in SCLC.
Clinical decision making requires evaluable disease status
characteristics. Such variables are essential in both diagnosis
and follow-up of small-cell lung cancer (SCLC). Numerous
qualitative and quantitative clinical and biochemical data are
often available. so that it is difficult to select the most useful
elements.
Various laboratory tests are widely used. as the initial step.
in establishing the assessment of the disease (Cohen et al..
1981; Souhami et al., 1985). Two variables seem interesting
in SCLC. The tumour marker serum neuron-specific enolase
(S-NSE) has been found to be a potentially useful indicator
of disease activity (Carney et al., 1982; Aroney et al., 1984;
Adewole et al., 1987). S-NSE is significantly related to extent
of disease (Carney et al., 1982; Akoun, 1985; J0rgensen,
1989), to response duration (Jorgensen et al., 1992), and to
prognosis (Jorgensen et al., 1988; Johnson et al., 1993). The
routine laboratory parameter serum lactate dehydrogenase
(S-LDH) is in SCLC a strong prognostic factor (Cohen et al.,
1981; Osterlind et al., 1983), and an increase in S-LDH level
is often a sign of progressing metastases, especially in the
liver and bone marrow (Kn'stjansen et al., 1986; Sagman et
al.. 1991). Consequently, both markers might be potential
disease monitors in progressive SCLC.
High capability to discriminate between no disease and
progressive disease is an important quality for a disease
monitor. Another important question is the relative increase
of the marker, i.e. the signal-to-noise ratio. The aim of the
present investigation was a comparison of S-NSE and S-
LDH at the time of diagnosis, during remission and at
progressive disease (PD). The aim was to investigate how
well changes in S-NSE and S-LDH correlated, and to
evaluate their diagnostic efficacy in SCLC.
Materials and methds
Twenty-seven patients with SCLC referred to The Finsen
Institute, Rigshospitalet, for treatment were included. Pre-
treatment evaluation included histological diagnosis accord-
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ing to the WHO classification (WHO. 1982) and disease
classification into limited (LD) versus extensive (ED).
Sera for S-NSE and S-LDH measurements were obtained
prior to treatment and before every new treatment cycle. i.e.
every 3-4 weeks, and patients were followed until their
terminal illness. Routine blood tests. general examination,
and chest radiography were performed before each new treat-
ment cycle.
Response evaluations were classified according to the
WHO guidelines (WHO. 1979). PD was defined as the
appearance of any new lesion not previously identified or an
estimated increase of 25% or more in existing lesions.
Relapse was identified by bronchoscopy, radiographs and
other relevant procedures. Patients obtaining complete or
partial response (CR, PR) followed by diagnosed progressive
disease were eligible for the study.
S-NSE was analysed by the Pharmacia RIA method at the
Diagnostic Development Unit, University of Leeds; the
upper reference value was set to 12.5jg 1'. S-LDH was
analysed by our routine laboratory according to the Nordic
recommendation (Scandinavian Society) and the upper
reference value set to 450 U I-'.
S-NSE and S-LDH changes were correlated to disease
status. The markers were assessed for their relative increase
in relation to upper reference limits. The diagnostic efficacy
of a marker to indicate CRTPR or PD was described by the
receiver operating characteristics (ROC curves), and the diag-
nostic power function tested by the Mann-Whitney test
(Siegel, 1988).
Results
At inclusion 15 patients had LD and 12 ED. All but one
were women. The median age was 58 years. All obtained
objective remission. Eighty-five per cent of all pretreatment
S-NSE values were increased compared with 37% of the
S-LDH values (for further details see Table I).
The marker values had normalised at re-evaluation except
in three patients. One CR patient had a single increased
S-NSE during follow-up, one PR patient experienced a
steady S-NSE> 12.5 jig 1-' and S-LDH was marginally in-
creased in one PR patient. During follow-up small oscilla-
tions were observed in both markers. Out of a total of 317
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follow up samples S-NSE was > 12.5 iLg I' in five samples
from four patients (median S-NSE 5.91gI-', range 2.0-24.4
jig 1-') and S-LDH in 12 samples, from nine patients (median
S-LDH 330 U 1-', range 132-746 U 1-'). For further details,
see Table II.
All patients expenenced PD. Graphic analysis of each case
showed exponential increments in S-NSE at the time of
progression. PD was in 93% of patients associated with an
increase in S-NSE (median 42.6ligl-', range 7.5-168.6
jug 1'). Two patients had S-NSE<12.5 jLg 1' throughout the
whole course, and S-LDH was at PD increased in only 56%
(median 550 U 1. range 276-2,120 U 1-'). The marker in-
crease preceded clinical progression by 20-50 days for S-
NSE in ten patients and for S-LDH in five. A more precise
assessment of lead time was impossible with a sample interval
of 1 month. S-NSE increments at PD quantitatively exceeded
the S-LDH changes. Highest S-NSE increment in PD was 12
times the upper reference limit compared with a maximum
4.7-fold increment in S-LDH (Figure 1).
Figure 2 shows the ROC curves for S-NSE and S-LDH.
These curves illustrate the relative diagnostic accuracy of the
tests in discriminating between CR or PR versus PD. Low
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Figure 2 Receiver operating characteristics (ROC) curves of 5-
NSE and S-LDH in discriminating progressive disease (PD) ver-
sus complete response (CR). * = S-NSE. + = S-LDH.
Table I Increased pretreatment S-NSE and S-LDH values in
relation to stage, disease and to response to therapy
Limited disease (%) Extensive disease (%)
S-NSE S-LDH S-NSE S-LDH
CR 86 (6 7) 14 (1 7) 100 (3,3) 33 (1 3)
PR 88 (7 8) 50 (4/8) 78 (7,9) 44 (4'9)
The figures represent the percentage of patients with pretreatment
increased values (>12.5 ug1-' for S-NSE and >450Ul-' for
S-LDH).
Table H Marker levels at clinical evaluation benchmarks
Pretreatment Day 90 Nadir n
S-NSE (pglg')
Range 6.7- 150 2.7-24.4 2.2- 11.2 27
Median 26 5.4 4.4
S-LDH (U-1')
Range 218- 1945 197-527 141 -439 27
Median 396 295 273
Nadir marker levels were observed randomly during follow-up.
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Figre I The marker increments in relation to upper reference
limits: S-NSE 12.5ligl-' and S-LDH 450UI-'.
values of reference limits resulted in higher sensitivity but
lower specificity. A sensitivity of 0.93 and a specificity of 0.90
was achieved for a S-NSE cut-off point of 12.5jg 1-1. The
applied S-LDH reference limit (450 U 1') resulted in a sen-
sitivity of 0.68 and a specificity of 0.90. The combined
specificity of 0.63 and sensitivity of 0.30 did not improve the
accuracy. The diagnostic efficacy for separate markers was
maximal at the applied cut-off levels: S-NSE 0.92 and S-
LDH 0.70. The difference in diagnostic power for the two
tests was significant (P<0.0008). All distributions were des-
cribed by a log Gaussian distribution.
Ds~
The clinical importance of a serum tumour marker depends
on how well it reflects changes in tumour status and on the
proportion of patients who have a positive marker. Ideally,
all patients should have a positive pretreatment marker, but
85%, as seen in S-NSE, is acceptable and currently the best
recorded in SCLC (Osterlind et al., 1983; Akoun et al., 1985;
Splinter et al., 1987; J0rgensen et al., 1988). Another impor-
tant question is the ability of the marker to reflect disease
status. Increased S-NSE was detected in 85% at inclusion
and 93% at PD, while S-LDH had a disease correspondence
of 37% at inclusion and 56% at PD. The low incidence of
increased S-LDH values might be explained by the careful
clinical follow-up of patients, resulting in an early detection
of PD.
Both of these enzyme markers might be expected to carry
information on disease progression. The disease relation of
S-NSE is explained by its derivation from the tumour. S-
LDH has been shown to be positively correlated with both
liver and bone marrow metastases (Sagman et al., 1991).
Both markers are informative in PD and are significant
prognostic factors in SCLC (J0rgensen et al., 1988),
encouraging the use of both markers in the management of
SCLC. Our finding of an exponential rise in S-NSE at PD is
in accordance with the study by Splinter et al. (1987). In our
investigation a rise in marker level was defined as stable if
two or more sample results showed an identical tendency.
During response we often found small oscillations below the
reference limit in both S-NSE and S-LDH values, but we did
not observe the high-amplitude S-NSE spikes of up to
35 jg 1' recorded by Muiller et al. (1992). The signal changes
relating to disease status were higher for S-NSE than for
S-LDH. S-NSE thus provides a higher proportion of in-
creased values in PD with a better signal-to-noise ratio than
S-LDH. This prompts us to conclude that S-NSE should
replace S-LDH as prognostic factor and disease activity
monitor in SCLC.S-NSE IN PROGRESSIVE SCLC 761
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